ALSF Childhood Cancer Research Grants
With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Modeling familial platelet disorder associated RUNX1 mutations in mice||University of Massachusetts Medical School / Lucio Castilla, PhD||Familial RUNX1 Research Grants||2020||Massachusetts|
|Drug Screen for FPD/AML Therapeutics||Children's Hospital of Philadelphia / Mortimer Poncz, MD||Familial RUNX1 Research Grants||2017||Pennsylvania|
|Role of Inflammatory Microenvironment in Clonal evolution and Progression from FPD to AML||Oregon Health & Science University / Anupriya Agarwal, PhD||Familial RUNX1 Research Grants||2017||Oregon|
|Modeling RUNX1-Associated Clonal Hematopoietic Disorders in Zebrafish||Boston Children's Hospital / Leonard Zon, MD||Familial RUNX1 Research Grants||2016||Massachusetts|
|Pharmacologic Enhancement of Residual Wild Type RUNX1 Protein Activity in FPD/AML||Boston Children's Hospital / Alan Cantor, MD, PhD||Familial RUNX1 Research Grants||2016||Massachusetts|
|Identifying Therapeutic Targets to Prevent Progression of Familial RUNX1 Disorder to AML Using Novel iPSC Models||Icahn School of Medicine at Mount Sinai / Eirini Papapetrou, MD/PhD||Familial RUNX1 Research Grants||2016||New York|
|Characterization of Pre-Leukemia Associated with Familial RUNX1 Mutations||Stanford University / Ravi Majeti, MD/PhD||Familial RUNX1 Research Grants||2016||California|
|Restoring RUNX1 Levels in FPD/AML||University of Washington, Seattle / Marshall Horwitz, MD/PhD||Familial RUNX1 Research Grants||2016||Washington|
|GD2-directed CAR T cell therapy for H3K27M+ spinal cord diffuse midline glioma||Board of Trustees of the Leland Stanford Junior University / Michelle Monje||Catalyst Grants||2021||California|
|Targeting Spinal Ependymoma and Other Gliomas Using Novel Genetically Defined Models||The Johns Hopkins University School of Medicine / Charles Eberhart, MD, PhD||Catalyst Grants||2019||Maryland|